Proteon Therapeutics to Present at the Cowen and Company 39th Annual Health Care Conference on March 11th

WALTHAM, Mass., March 04, 2019 (GLOBE NEWSWIRE) -- Proteon Therapeutics Inc. PRTO, a company developing novel, first-in-class therapeutics to address the medical needs of patients with kidney and vascular diseases, today announced that Company management will present at the Cowen and Company 39^th Annual Health Care Conference in Boston on Monday, March 11, 2019, at 4:50 pm ET.

About Proteon Therapeutics

Proteon Therapeutics is committed to improving the health of patients with kidney and vascular diseases through the development of novel, first-in-class therapeutics. Proteon's lead product candidate, vonapanitase, is an investigational drug intended to improve hemodialysis vascular access outcomes. Proteon has completed enrollment in PATENCY-2, a Phase 3 clinical trial evaluating vonapanitase in patients with chronic kidney disease (CKD) undergoing surgical creation of a radiocephalic arteriovenous fistula for hemodialysis. Proteon is also evaluating vonapanitase in a Phase 1 clinical trial in patients with peripheral artery disease (PAD). For more information, please visit www.proteontx.com.

Investor Contact

George Eldridge, Proteon Therapeutics, Senior Vice President and Chief Financial Officer

781-890-0102

geldridge@proteontherapeutics.com

Media Contact

Ann Stanesa, Ten Bridge Communications

617-230-0347

proteon@tenbridgecommunications.com